SCHEMBL1564760

SCHEMBL1564760

Clc1c[nH]c2ncc(Br)cc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITK Q08881 12/20 0.54
JAK2 O60674 4/20 0.54
AURKA O14965 3/20 0.54
MAP4K4 O95819 3/20 0.54
FGFR1 P11362 3/20 0.54
FLT1 P17948 3/20 0.54
KDR P35968 3/20 0.54
CLK2 P49760 3/20 0.54
CDK5 Q00535 3/20 0.54
MAP4K2 Q12851 3/20 0.54
DYRK1A Q13627 3/20 0.54
AURKB Q96GD4 3/20 0.54
CLK4 Q9HAZ1 3/20 0.54
PRKD3 O94806 2/20 0.54
TAOK1 Q7L7X3 2/20 0.54
IGF1R P08069 2/20 0.54
JAK3 P52333 2/20 0.54
LIMK1 P53667 2/20 0.54
NTRK2 Q16620 2/20 0.54
PLK4 O00444 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1565867 0.77 DYRK1A (0.54) ITKJAK2AURKAMAP4K4FGFR1
SCHEMBL68662 0.77 DYRK1A (0.58) ITKJAK2AURKAMAP4K4FGFR1
SCHEMBL1564507 0.77 GSK3B (0.56) ITKJAK2AURKAMAP4K4FGFR1
SCHEMBL23030509 0.77 BTK (0.39) ITKJAK2BTKPRMT5WDR77
SCHEMBL1566306 0.77 ITK (0.54) ITKJAK2AURKAMAP4K4FGFR1
SCHEMBL24005850 0.77 PRMT5 (0.42) ITKJAK2DYRK1ABTKPRMT5
SCHEMBL11968456 0.77 DYRK1A (0.54) ITKJAK2AURKAMAP4K4FGFR1
SCHEMBL91445 0.77 AXL (0.41) ITKJAK2BTKPRMT5WDR77
SCHEMBL20033884 0.77 BTK (0.39) ITKJAK2BTKPRMT5WDR77
Ammonia Solution, Strong SCHEMBL27874537 0.76 DYRK1A (0.57) ITKJAK2AURKAMAP4K4FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240327412-A1 FACTOR XIIA INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2024-10-03 US disclosed
CN-118488947-A Condensed ring substituted six-membered heterocyclic compound, preparation method and application thereof 劲方医药科技(上海)有限公司 2024-08-13 CN disclosed
US-20240182465-A1 FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2024-06-06 US disclosed
US-20240059691-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2024-02-22 US disclosed
WO-2024038282-A1 2-AZA- AND 2-OXABICYCLO[2.1.1]HEXANE DERIVATIVES AS FACTOR XIIA ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2024-02-22 WO disclosed
EP-4303216-A1 FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Genfleet Therapeutics (Shanghai) Inc. (CN) 2024-01-10 EP disclosed
EP-4294798-A1 FACTOR XIIA INHIBITORS Kalvista Pharmaceuticals Limited (GB) 2023-12-27 EP disclosed
CN-116981661-A Condensed ring substituted six-membered heterocyclic compound, preparation method and application thereof 劲方医药科技(上海)有限公司 2023-10-31 CN disclosed
EP-4255900-A2 ENZYME INHIBITORS Kalvista Pharmaceuticals Limited (GB) 2023-10-11 EP disclosed
CN-116829547-A Factor XIIa inhibitors 卡尔维斯塔制药有限公司 2023-09-29 CN disclosed
US-8637542-B2 Kinase inhibitors and methods of use INTELLIKINE, INC. (US) 2014-01-28 US disclosed
US-8637542-B2 Kinase inhibitors and methods of use INTELLIKINE, INC. (US) 2014-01-28 US disclosed
EP-2308877-B1 IMIDAZOPYRIDIN-2-ONE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2014-01-22 EP disclosed
US-20130338156-A1 IMIDAZOPYRIDIN-2-ONE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-12-19 US disclosed
US-8436012-B2 Imidazopyridin-2-one derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-05-07 US disclosed
EP-2308877-A1 IMIDAZOPYRIDIN-2-ON DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2011-04-13 EP disclosed
US-20110082138-A1 IMIDAZOPYRIDIN-2-ONE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-04-07 US disclosed
US-20110077268-A1 KINASE INHIBITORS AND METHODS OF USE INTELLIKINE LLC 2011-03-31 US disclosed
US-20110077268-A1 KINASE INHIBITORS AND METHODS OF USE INTELLIKINE LLC 2011-03-31 US disclosed
WO-2009114870-A2 KINASE INHIBITORS AND METHODS OF USE INTELLIKINE, INC. (US) 2009-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110082138-A1 IMIDAZOPYRIDIN-2-ONE DERIVATIVES MTOR, MAPKAP1, RICTOR ITK 2222/4885JAK2 184/4885AURKA 1063/4885
US-20240327412-A1 FACTOR XIIA INHIBITORS F11, F13B, F12 ITK 2548/4885JAK2 1564/4885AURKA 2267/4885
US-20110077268-A1 KINASE INHIBITORS AND METHODS OF USE MAP3K20, MAP3K1, PDPK1 ITK 432/4885JAK2 321/4885AURKA 425/4885
US-20240059691-A1 ENZYME INHIBITORS SERPINB1, XDH, ACE ITK 4016/4885JAK2 2532/4885AURKA 2718/4885
US-20130338156-A1 IMIDAZOPYRIDIN-2-ONE DERIVATIVES MTOR, MAPKAP1, RICTOR ITK 2222/4885JAK2 184/4885AURKA 1063/4885
US-20240182465-A1 FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF WEE1, WEE2, HASPIN ITK 24/4885JAK2 2791/4885AURKA 1400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.